Phyllanthus Amarus.

Silymarin flavonolignans stabilise the hepatocyte membrane and support glutathione levels, while Phyllanthus lignans are described as acting on antioxidant enzyme expression. The two plant chemistries support normal liver function by different routes.

NAC supplies cysteine, the rate limiting amino acid for glutathione synthesis, which phase two conjugation in the liver depends on. Phyllanthus lignans are described as supporting the antioxidant enzymes that use that glutathione pool.

Schisandra dibenzocyclooctadiene lignans and Phyllanthus lignans both influence hepatic phase one and phase two enzyme expression. They are traditionally combined in liver support formulas.

Curcumin activates Nrf2 signalling, which raises transcription of glutathione S transferase and other phase two enzymes. That is the same conjugation capacity Phyllanthus is used to support.

Cynarin and caffeoylquinic acids in artichoke increase bile secretion, which is the route conjugated metabolites leave the liver. Adding flow to a formula built around hepatic enzyme support completes the pathway.

Piperine inhibits intestinal glucuronidation and P-glycoprotein efflux, which raises systemic exposure to poorly absorbed plant lignans and polyphenols. It is added to Phyllanthus formulas for that reason.

Phyllanthus is tannin rich, and hydrolysable tannins bind non-heme iron in the gut into complexes that are not absorbed. Space an iron dose away from the herb.

Pyridoxal-5-phosphate is the cofactor for alanine glyoxylate aminotransferase, the enzyme that diverts glyoxylate away from becoming oxalate in the liver. That addresses oxalate at its source, upstream of anything happening in the urinary tract. Urinary oxalate is a measurable marker of that handling.

Magnesium competes with calcium for oxalate in solution and raises the concentration at which calcium oxalate crystals will nucleate and grow. Plant extracts reported to act on crystal aggregation work on the same physical process from a different angle. Crystallisation behaviour in urine is a marker, not a clinical endpoint.

Calcium taken with a meal binds food oxalate in the intestine and carries it out in stool, which lowers how much oxalate is absorbed and later filtered. Timing is the whole mechanism: with the meal it binds oxalate, away from meals it does not. This is settled physiology.

Ascorbate degrades to oxalate, and high supplemental doses raise urinary oxalate measurably in controlled studies. That works against a formula aimed at urinary crystal handling. Worth flagging as a genuine counter-pairing rather than a synergy.

Potassium supplied as an organic acid salt raises urinary citrate and pH, and citrate complexes calcium so it is less available to bind oxalate. Plant lignans and tannins act on crystal surfaces rather than on urine chemistry. The two touch the same problem at different points; potassium chloride does not carry the same alkali effect.

Certain gut bacteria carry oxalyl-CoA decarboxylase and break dietary oxalate down before it can be absorbed. Colonisation and persistence are the practical limits, and strain identity matters more than the category label. Faecal and urinary oxalate are handling markers.

Phyllanthin and hypophyllanthin are lipophilic and dissolve poorly in gut fluid, which the bioavailability review identifies as the bottleneck. Phospholipid complexation is a standard formulation answer to that specific problem. It changes delivery, not mechanism.

Phyllanthus species are rich in ellagitannins and gallate esters, and EGCG is handled by the same methyltransferase and glucuronidation capacity. Combined, they compete for that capacity. Both also bind luminal non-heme iron.

Ellagitannins and hydrolysable tannins bind zinc and iron in the gut lumen and lower their absorption, the same mechanism behind reduced mineral uptake from tannin-rich beverages. A tannin-heavy whole-plant extract taken with a mineral dose is therefore a spacing question. A couple of hours apart is the usual answer.

Both quercetin and the flavonoid fraction of this plant are substrates for intestinal sulfotransferases and BCRP efflux. Together they compete for finite handling. That shifts each one's plasma profile without a demonstrated added benefit.

Both plants appear in traditional practice for increasing urine output and are commonly blended for that reason. Stacking two agents that raise urine volume also stacks their effect on fluid and electrolyte balance. The pairing rests on traditional use, not on a combination trial.

Lipoic acid is reduced intracellularly to dihydrolipoate, which regenerates glutathione and other thiols, while plant polyphenols act largely on extracellular and membrane radicals. The two work in different compartments. Compartment coverage is the argument, and neither claim is an outcome.

Glutathione is built from glutamate, cysteine and glycine, and glycine availability can become limiting when synthesis rate rises. Supporting the substrate side complements a polyphenol acting on redox signalling. Glutathione concentration is a marker of redox status.

Taurine conjugates bile acids and so influences their solubility and enterohepatic recycling. That sits on the bile handling side of normal liver function rather than on the antioxidant side. Mechanistic complement only, with no combination evidence.